Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance

Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance

Multiple myeloma (MM) remains a common hematologic malignancy with a 10-year survival rate below 50%, which is largely due to disease relapse and resistance. The lack of a simple and practical approach to establish myeloma patient-derived xenograft (PDX) hampers translational myeloma research. Here,...

Full description

Bibliographic Details
Main Authors: Yanhua Yue, Yang Cao, Xunyuan Mao, Fei Wang, Peng Fan, Long Qian, Shuxin Guo, Feng Li, Yanting Guo, Tongbing Chen, Yan Lin, Weimin Dong, Yue Liu, Yuhui Huang, Weiying Gu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
multiple myeloma
patient-derived xenograft
anlotinib therapy
tumor angiogenesis
tumor-associated macrophages
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.894279/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.894279/full

Similar Items